Pioneering Bristol firm Ziylo has been bought by global healthcare company Novo Nordisk in a deal which could be worth around $800m (£628m) and could also trigger a breakthrough in the treatment of diabetes. A spin-out company from the University of Bristol, Ziylo will use the funds from the...